Latest public offering nets $601mm for bluebird bio

Immunotherapy and gene editing firm bluebird bio Inc. netted $601mm through the public offering of 3.9mm common shares (including the overallotment) at $162.50. Proceeds are earmarked for the following: future development of a gene therapy for severe sickle cell disease; the company's portion of development, manufacturing, and commercialization costs related to multiple myeloma CART therapy bb2121, in partnership with Celgene; Phase I study of bb21217, also for multiple myeloma and part of the Celgene agreement; Phase III trial of LentiGlobin candidate HGB212 for transfusion-dependent beta-thalassemia; continued advancement of the company's commercial infrastructure to support upcoming product launches in the US and Europe; and for ongoing manufacturing and R&D needs.